
Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.

April 5, 2023
Health technology assessment (HTA) submissions require cost effectiveness analyses based on comparative effectiveness...
Read article




May 5, 2022
Interview with Grammati Sarri on Moderating an Issue Panel 2022
While randomized control trials remain the industry gold-standard for regulatory and reimbursement submissions, there...
Read article

April 29, 2022
An Interview with Gabriel Tremblay on his Poster Contributions to ISPOR US 2022
At ISPOR US 2022, Cytel’s HEOR & RWE experts will be contributing to a range of Issue Panels, In-person Podium...
Read article

April 13, 2022
Join Cytel’s HEOR Consultants at ISPOR US 2022
The Life Sciences landscape has seen an impactful digital evolution in the past two years. The pandemic has accelerated...
Read article

June 10, 2021
Myths surrounding the use of synthetic control arms in clinical trials: Part 1
Over the past decade, single arm trials have emerged as an accepted way of assessing a new treatment intervention....
Read article

April 29, 2021
Advances in HEOR: An Interview with Anna Forsythe
After twenty years in pharma, Anna Forsythe was frustrated by traditional vendors who used outdated methods to prepare...
Read article

April 13, 2016
HTAs: Adjusting Overall Survival for Treatment Switch
We continue our series of blogs covering the expert presentations from the EAST User Group Meeting. Consultant Claire...
Read article